School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Surrozen, Inc./DE SRZN

Healthcare · Biotechnology

$24.76last close 2026-10-12 · market cap $291.02M · delayed data

Trailing returns

1M+30.32%
3M+6.77%
6M-12.20%
1Y+79.86%
5Y-73.76%

Basis: Adjusted daily closes.

What it does

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Open SRZN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies